{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urticaria/prescribing-information/non-sedating-antihistamines/","result":{"pageContext":{"chapter":{"id":"71f6ce5f-ac94-5ef4-9a02-0aa362883a44","slug":"non-sedating-antihistamines","fullItemName":"Non-sedating antihistamines","depth":2,"htmlHeader":"<!-- begin field 4ebc1064-859e-4cbc-9d69-0bc9c27a6c4c --><h2>Non-sedating antihistamines</h2><!-- end field 4ebc1064-859e-4cbc-9d69-0bc9c27a6c4c -->","summary":"","htmlStringContent":"<!-- begin item d9147fb8-c048-4a1d-8047-81d49466f871 --><!-- end item d9147fb8-c048-4a1d-8047-81d49466f871 -->","topic":{"id":"bfdbbcbf-5a56-51b8-b0aa-78a059b4cfec","topicId":"73ccd3ba-b5a5-4a3c-98b2-d838dd8a3c58","topicName":"Urticaria","slug":"urticaria","lastRevised":"Last revised in March 2020","chapters":[{"id":"7068e840-7bdb-5596-a56f-1c930bd4b8c4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d6e4cfbd-5e36-5755-a780-8091e4b5f146","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9dde1c08-758f-55bb-b187-0203ded94048","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3daa7b54-d234-587b-8a56-1bb5cae1efe4","slug":"changes","fullItemName":"Changes"},{"id":"54c42276-0c06-5c18-825f-3c440cb30dfe","slug":"update","fullItemName":"Update"}]},{"id":"5cff12c3-445b-5613-bf5d-dc48effe6502","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9abed54c-a9ed-58d4-bfce-3f0dddd49698","slug":"goals","fullItemName":"Goals"},{"id":"c2f713b4-e2ec-5e5e-be8f-5c4285be0b6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e829abf6-8412-500f-9425-647958addf97","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"92b040fe-6318-560a-9ae0-6f98a6aa9c09","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2d2f38df-88c4-5895-915d-199eefc9b02a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d51180cd-461f-58ad-8f03-20d63965abfb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7fce165-b445-5aa6-9ec9-6ec8016f4bee","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a5d17f35-ddfe-5931-bfe4-b7dc039baea0","slug":"definition","fullItemName":"Definition"},{"id":"90888c1e-cd37-5fdf-9d0d-b71e51bf56c3","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"76d2cc5e-4a3e-5032-8eed-d4010ace1ae7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"507a6931-af71-54ae-a8e7-2b4393c2a41b","slug":"complications","fullItemName":"Complications"},{"id":"091f4740-5801-5ac0-83bd-a7ebbc2a2848","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fc3a9cf3-3dd4-5456-94e1-90c38c83a0b1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"513fb45b-36c0-59b5-8f88-13b10509caee","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e2100cac-0eb7-55e6-b138-9cbc110f1b71","slug":"investigations","fullItemName":"Investigations"},{"id":"2da7bf77-7798-5632-97d4-64d5463f8cde","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1a1cabda-9d82-5131-8852-db2d844e0b46","fullItemName":"Management","slug":"management","subChapters":[{"id":"f797a7bd-9ca9-523b-8f1e-e2afc927c4ab","slug":"managing-urticaria","fullItemName":"Scenario: Managing urticaria"}]},{"id":"3c7854e6-2fe5-5632-9b63-69f2773b7dd1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"71f6ce5f-ac94-5ef4-9a02-0aa362883a44","slug":"non-sedating-antihistamines","fullItemName":"Non-sedating antihistamines"},{"id":"8888f0f6-7dd8-55fb-afc0-9e5df55b825a","slug":"sedating-antihistamines","fullItemName":"Sedating antihistamines"},{"id":"b8336773-e3de-5ec0-a85b-93fd72ff7869","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"c88fe5a9-a559-5661-9a1f-e0ee93078a4d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e9950b4f-8af1-5d4b-b531-431ac4a731bb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"729aa2a2-070b-51ed-9ecf-c29549914b66","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a30a2a17-7629-5022-a313-848d8264fb35","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f6d1c75a-6a3d-5326-97ca-baff36370740","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dd5a897e-e7d5-5c98-88b6-35014f9a5dde","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6d27a969-ded2-5d9d-9321-f65e47426edf","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d45859d-1b50-538f-84fa-568f43b5c283","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3c7854e6-2fe5-5632-9b63-69f2773b7dd1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"750e8cc1-58a9-58a5-a1ea-7feb152fca97","slug":"choice-of-antihistamine","fullItemName":"Choice of antihistamine","depth":3,"htmlHeader":"<!-- begin field 7b4f2f20-7c28-45c7-ab26-a73800a8aa05 --><h3>Which non-sedating antihistamine should I prescribe?</h3><!-- end field 7b4f2f20-7c28-45c7-ab26-a73800a8aa05 -->","summary":"","htmlStringContent":"<!-- begin item 28dc2d29-da59-4b68-88b2-a73800a8a8aa --><!-- begin field c35d9775-832b-4c40-b04d-a73800a8aa05 --><ul><li><strong>For most adults, </strong>cetirizine, loratadine, and fexofenadine are usual choices as their long-term safety has been well established and their once-daily dosage may improve adherence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>]. However, any suitable non-sedating antihistamine can be considered as all are licensed for the treatment of urticaria, and there is no strong evidence that one is more effective than the other [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Sharma, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].</li><li><strong>In children,</strong> cetirizine, loratadine, or fexofenadine are usual choices and have been well studied [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Fitzsimons, 2015</a>]. <ul><li>The choice of antihistamine should depend on the age of the child (<a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/prescribing-information/non-sedating-antihistamines/#licensed-doses\">licensed ages</a> differ), availabilities (as not all are available in syrup form), and preference (for example what has worked in the past).</li><li>The British National Formulary for Children (BNFC) states that desloratadine or levocetirizine should be reserved for children who cannot tolerate other treatments, because they do not confer any additional benefit [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF for Children, 2017</a>].</li></ul></li><li><strong>During pregnancy, </strong>oral antihistamines should be avoided where possible, especially during the first trimester. However, if a non-sedating antihistamine is required, loratadine is recommended as there is considerable clinical experience with its use in pregnancy, with no increase in the rate of congenital abnormalities [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>]. Cetirizine, desloratadine (an active metabolite of loratadine), or levocetirizine (an isomer of cetirizine) may also be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>].<ul><li>Most manufacturers of antihistamines advise avoiding their use during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>]; however, there is no evidence of teratogenicity with their use.</li><li>A systematic review and meta-analysis on the risk of adverse pregnancy outcome after first trimester exposure to H1-antihistamines<strong> </strong>found that they do not appear to be associated with an increased risk of major malformation or other adverse fetal outcomes (spontaneous abortions, prematurity, stillbirth, and low birth weight) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Etwel, 2017</a>].</li></ul></li><li><strong>During breastfeeding,</strong> loratadine and cetirizine are recommended. The lowest effective dose for the shortest period of time should be prescribed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].<ul><li>Most manufacturers of antihistamines advise avoiding their use during breastfeeding as most antihistamines are present in breast milk (in varying amounts) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>].</li><li>However, LactMed (a US drugs and lactation database) states that:<ul><li>Loratadine would not be expected to cause any adverse effects in breastfed infants due to its lack of sedation and low milk levels, but it might have a negative effect on lactation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">LactMed, 2013</a>]. </li><li>Cetirizine is probably acceptable during breastfeeding if given in small, occasional doses. However, larger doses or more prolonged use may cause drowsiness and other effects in the infant, or decrease the milk supply particularly before lactation is well established [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">LactMed, 2016</a>]. </li></ul></li></ul></li></ul><!-- end field c35d9775-832b-4c40-b04d-a73800a8aa05 --><!-- end item 28dc2d29-da59-4b68-88b2-a73800a8a8aa -->","subChapters":[]},{"id":"df80b019-ca0c-5c92-8338-64fb5044d17a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 82c01e7c-c90b-48bf-9685-a738017617fa --><h3>What are the contraindications and cautions?</h3><!-- end field 82c01e7c-c90b-48bf-9685-a738017617fa -->","summary":"","htmlStringContent":"<!-- begin item 3c4818a8-8c77-40df-8588-a7380176160f --><!-- begin field 7db30832-86b1-4bbb-874b-a738017617fa --><ul><li><strong>Do not prescribe:</strong><ul><li><strong>Cetirizine to people with:</strong><ul><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 10 mL/minute/1.73 m<sup>2)</sup>.</li><li>Acute porphyria.</li></ul></li></ul></li></ul><ul><li><strong>Prescribe:</strong><ul><li><strong>Cetirizine with caution to </strong><strong>people with</strong> renal impairment.<ul><li>If eGFR is 30–50 mL/minute/1.73 m<sup>2</sup>, prescribe half the normal <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/prescribing-information/non-sedating-antihistamines/#licensed-doses\">dose</a>.</li><li>If eGFR is 10–30 mL/minute/1.73 m<sup>2</sup>, use half normal dose and reduce dose frequency to alternate days.</li></ul></li><li><strong>Loratadine with caution to people with</strong> hepatic impairment.<ul><li>Reduce dose frequency to alternate days in severe impairment.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>]</p><!-- end field 7db30832-86b1-4bbb-874b-a738017617fa --><!-- end item 3c4818a8-8c77-40df-8588-a7380176160f -->","subChapters":[]},{"id":"76a4ce4c-3b0c-599c-9911-b88ecfe41f2f","slug":"licensed-doses","fullItemName":"Licensed doses","depth":3,"htmlHeader":"<!-- begin field 95a0d2a5-07bc-4d39-bffd-a73800aa6859 --><h3>What are the licensed doses for chronic idiopathic urticaria?</h3><!-- end field 95a0d2a5-07bc-4d39-bffd-a73800aa6859 -->","summary":"","htmlStringContent":"<!-- begin item ef6cb684-0e8c-4f71-912d-a73800aa66ac --><!-- begin field 1042acf5-43d5-4ab8-b9f8-a73800aa6859 --><ul><li><strong>The licensed oral doses of cetirizine are:</strong><ul><li>Children aged 2 years to 5 years — 2.5 mg twice daily.<ul><li>Cetirizine is not licensed for use in children aged under 2 years, but the British National Formulary for Children (BNFC) recommends an unlicensed dose of 250 micrograms/kg twice daily for children aged 1 year [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF for Children, 2017</a>]. </li></ul></li><li>Children aged 6 years to 11 years — 5 mg twice daily.</li><li>Adults and children aged 12 years and over — 10 mg once daily.</li></ul></li><li><strong>The licensed oral doses of loratadine ar</strong><strong>e:</strong><ul><li>Children aged 2 years to 11 years and body weight up to 31 kg — 5 mg once a day.</li><li>Children age 2 years to 11 years and body weight 31 kg and over —10 mg once a day.</li><li>Adults and children aged 12 years and over — 10 mg once a day.</li></ul></li><li><strong>The licensed oral dose of fexofenadine is</strong><strong>:</strong><ul><li>Adults and children aged 12 years and over — 180 mg once a day.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF for Children, 2017</a>]</p><!-- end field 1042acf5-43d5-4ab8-b9f8-a73800aa6859 --><!-- end item ef6cb684-0e8c-4f71-912d-a73800aa66ac -->","subChapters":[]},{"id":"09a6c190-a8d9-5c8a-a971-c852443cfcd6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 0446d488-9ecb-4924-a8ea-a73800a8e451 --><h3>What are the possible adverse effects?  </h3><!-- end field 0446d488-9ecb-4924-a8ea-a73800a8e451 -->","summary":"","htmlStringContent":"<!-- begin item 3f86acaf-6a0e-49d1-b510-a73800a8e342 --><!-- begin field f189727c-cd6d-4fcb-9dee-a73800a8e451 --><ul><li><strong>Non-sedating antihistamines are associated with a lower incidence of drowsiness and sedation</strong> (because they penetrate the blood–brain barrier to a lesser extent than sedating antihistamines) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Bernstein, 2014</a>]. However, these adverse effects may still occur.<ul><li>Fexofenadine and loratadine may cause sedation at doses exceeding the recommended doses.</li><li>Cetirizine may cause sedation at recommended doses.</li><li>The sedative effects of antihistamines are enhanced when combined with alcohol.   </li></ul></li><li><strong>Rare adverse effects of antihistamines include</strong> hypotension, palpitation, arrhythmias, extrapyramidal effects, dizziness, confusion, depression, sleep disturbances, tremor, convulsions, hypersensitivity reactions (including bronchospasm, angioedema, anaphylaxis, rashes, and photosensitivity reactions), blood disorders, liver dysfunction, nightmares, acute generalised exanthematous pustulosis, arthralgia and angle-closure glaucoma.</li><li>The manufacturer's SPC notes that desloratadine has been associated with an increased incidence of new-onset seizure in patients younger than 20 years of age.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">ABPI, 2020</a>]</p><!-- end field f189727c-cd6d-4fcb-9dee-a73800a8e451 --><!-- end item 3f86acaf-6a0e-49d1-b510-a73800a8e342 -->","subChapters":[]},{"id":"36686c36-2f26-543d-892d-8581c522fadc","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c3f5a5dd-8182-4bd8-b531-a73801688f8a --><h3>What drug interactions are associated with antihistamines?</h3><!-- end field c3f5a5dd-8182-4bd8-b531-a73801688f8a -->","summary":"","htmlStringContent":"<!-- begin item 0e584d6b-4972-419e-a76c-a73801688ce1 --><!-- begin field bc9d25b0-0d02-4d91-8e59-a73801688f8a --><ul><li><strong>Drug interactions associated with non-sedating antihistamines include:</strong><ul><li><strong>Ritonavir —</strong> plasma concentration of non-sedating antihistamines possibly increased by ritonavir. </li><li><strong>In addition for fexofenadine:</strong><ul><li><strong>Antacids —</strong> absorption of fexofenadine reduced by antacids. </li><li><strong>Rifampicin —</strong> effects of fexofenadine possibly reduced by rifampicin.</li><li><strong>Ulipristal acetate —</strong> the manufacturer of ulipristal acetate advises that fexofenadine is taken at least 1.5 hours before or after taking ulipristal.</li></ul></li><li><strong>In addition for loratadine:</strong><ul><li><strong>Cimetidine —</strong> the manufacturer of loratadine advises that plasma concentrations are possibly increased by cimetidine.</li><li><strong>Erythromycin —</strong> the manufacturer of loratadine advises that plasma concentrations are possibly increased by erythromycin.</li></ul></li></ul></li><li><strong>Drug interactions associated with all antihistamines include:</strong><ul><li><strong>Alcohol —</strong> increased sedative effect when antihistamines are taken with alcohol (possibly less effect with non-sedating antihistamines).</li><li><strong>Antidepressants (tricyclics, tricyclic-related, and monoamine oxidase inhibitors [MAOIs]):</strong><ul><li>Increased antimuscarinic and sedative effects when antihistamines are taken with tricyclics or MAOIs.</li><li>Possible increased antimuscarinic and sedative effects when antihistamines are taken with tricyclic-related antidepressants.</li></ul></li><li><strong>Antimuscarinics —</strong> increased risk of antimuscarinic adverse effects when antihistamines are taken with antimuscarinic drugs (dosage adjustment may be required).<ul><li>Note that many drugs have antimuscarinic effects. Concurrent use of two or more of such drugs can increase the risk of adverse effects, such as dry mouth, urine retention, and constipation. Concurrent use can also lead to confusion in the elderly. Interactions do not generally apply to inhaled antimuscarinics.</li></ul></li><li><strong>Anxiolytics, hypnotics, and opioids —</strong> increased sedative effect when antihistamines are taken with these groups of drugs.</li><li><strong>Betahistine —</strong> antihistamines theoretically antagonize the effects of betahistine.</li><li><strong>Milodrine —</strong> avoidance of antihistamines advised by manufacturer of midodrine.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>] </p><!-- end field bc9d25b0-0d02-4d91-8e59-a73801688f8a --><!-- end item 0e584d6b-4972-419e-a76c-a73801688ce1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}